Merck completed its $10.8 billion acquisition of portfolio company Prometheus Biosciences.
Prometheus Biosciences specializes in innovative diagnostics and precision medicine for inflammatory bowel disease (IBD), providing a suite of tests that guide patient care decisions throughout the patient journey
Prometheus Biosciences specializes in innovative diagnostics and precision medicine for inflammatory bowel disease (IBD), providing a suite of tests that guide patient care decisions throughout the patient journey.